Concerns About Eye Toxicity Could Limit GSK’s Myeloma Drug Potential
US FDA Flags Safety Ahead Of Meeting
Executive Summary
Company told more measures needed to limit damage to patients' eyes caused by antibody drug conjugate.
You may also be interested in...
GSK’s Myeloma Drug Gets AdComm Backing, But Limitations Remain Clear
The antibody-drug conjugate now looks set for US approval, but its limitations leave plenty of scope for CAR-T and bispecific rivals.
Precision Keeps Faith In Duchenne Gene-Editing After Lilly’s Exit
The company has pledged to continue developing its Duchenne in vivo gene editing therapy without Lilly, but will remain focused on its lead program in hepatitis B.
Boehringer Ingelheim Overtakes Bayer As Germany’s Biggest Pharma Company
The privately owned company is searching for a successor to Jardiance, while the outcome of US Inflation Reduction Act talks on price cuts to the blockbuster will be revealed in September.